ABSTRACI'. Deficiency of prolidase is frequently associated with skin lesions and mental retardation. Biochemically, the condition i s marked by iminodipeptiduria. We have investigated the feasibility of using donor erythrocytes to replace the deficient enzyme. Prolidase occurs in erythrocytes in an inactive form. If erythrocytes are incubated overnight at 37' C in the presence of 1 mM MnC12, the intracellular Mn++ concentration increases from 0.014 to 2.04 pg/ml. As a consequence, the activity of prolidase in hemolysates increases to 159 pmol glycyl-L-proline hydrolyzed/h/ml compared to 5 pmol/h/ml for hemolysates of cells incubated in the absence of Mn++. Hydrolysis of glycyl-L-proline by intact erythrocytes is reduced by the slow rate of iminodipeptide transport into the cell; however, intact cells hydrolyzed this substrate at a rate 10-20 times faster after preincubation with MnC12. After exogenous MnC12 is removed from the storage buffer, high levels of erythrocyte prolidase activity persist for at least 13 days. The kinetic parameters for intact activated erythrocytecatalyzed hydrolysis of glycyl-L-proline have been estimated. These values predict that donor erythrocytes, activated with Mn++ before transfusion could play a significant role in the recovery of proline from dietary sources of iminodipeptides in patients with prolidase deficiency. (Pediatr Res 24:709-712, 1988) Abbreviations glypro, glycyl-L-proline Km, Michaelis constant TBS, Tris-buffered saline TCA, trichloroacetic acid TRIS, tris (hydroxymethyl) aminomethane Vmax, maximal velocity Prolidase deficiency is a rare autosomal recessively inherited inborn error of metabolism. Prolidase (E.C. 3.4.13.9) is a dipeptidase with absolute specificity for dipeptides with carboxy terminal imino acids. The gene locus (PEPD) has been mapped to chromosome 19.
The clinical findings in prolidase deficiency are variable, but patients usually present with skin ulcers and recurrent infections and, frequently, with mild mental retardation. A characteristic dysmorphology has also been described. Biochemically, the condition is marked by massive iminodipeptiduria. The most abundant of these urinary iminodipeptides is glycylproline (1) . Some asymptomatic individuals have been detected by neonatal screening programs (2) , and by investigation of sibs of clinically affected probands (3, 4) .
Although the cause of the pathology is not known, it has been proposed that one or more of the symptoms may reflect a tissue deficiency of L-proline, which is not reclaimed in the absence of prolidase. Excretion of this amino acid, in bound form, has been estimated to vary between 20-30 mmol/day in some patients (5) . Although failure to recover the proline from iminodipeptides may play a role in the pathogenesis of prolidase deficiency it cannot account for all the symptomology. Numerous reports (3, (6) (7) (8) document the failure of oral administration of L-proline to relieve the dermatological lesions associated with prolidase deficiency.
Regardless of the pathologic mechanisms, many workers have considered the desirability of a mode of therapy for prolidase deficiency using enzyme replacement. Two groups (9, 10) attempted transfusion of patients deficient in prolidase with normal matched erythrocytes. In both cases no effect on iminodipeptiduria or upon clinical symptoms was seen despite the fact that in one case (9) , erythrocyte prolidase activity reached 35% of normal levels in the patient's circulation.
Despite disappointing initial results, enzyme replacement via blood transfusion remains an appealing prospect. The circulation is uniquely accessible to enzyme replacement vehicles and furthermore this compartment represents the final opportunity to reclaim the amino acids in iminodipeptides before they are cleared by the kidney. We have therefore investigated the regulation of erythrocyte prolidase activity in hemolysates and intact cells. Our results indicate that brief exposure of intact erythrocytes to low concentrations of Mn significantly activates intracellular prolidase without causing hemolysis. We discuss the implications of these findings for enzyme replacement therapy in prolidase deficiency.
MATERIALS AND METHODS
Preparation of blood cells and hemolysates. For most experiments expired human erythrocytes were obtained from the hospital blood bank. These preparations were 35 days old and had been stored in 63 ml of citrate-phosphate-dextrose-adenine at 4" C. For some experiments fresh blood was obtained by venipuncture of laboratory volunteers and rapid transfer into heparinized tubes.
Cells were separated from plasma or from anticoagulant by centrifugation at 2100 rpm at 22" C for 10 min. The cells were washed by resuspension in 10 mM Tris-HC1 pH 7.4-0.9% TBS and recentrifugation until all soluble hemoglobin was removed (usually three to four washes).
Hemolysates were prepared by dilution of washed erythrocytes with 1 vol of 10 mM Tris-HC1 pH 7.4. The resuspended erythrocytes were rapidly frozen in dry ice-ethanol or overnight at -20" C and thawed at 37" C.
For activation of prolidase in intact erythrocytes, the washed cells were suspended in I volume of TBS containing 0.5% glucose, 0.5% human serum albumin (Connaught Labs, Toronto, Canada), and 1/100 volume of Eagle's antibiotic preparation and incubated without shaking overnight at 37" C. Each activation was performed in parallel with one sample of the washed erythrocytes containing 0.5 mM MnC12 in the above buffer and an identical sample incubated in Mn-free buffer. After incubation, the cell suspension was centrifuged to remove Mn and any Hb released. Cells were then resuspended in TBS.
Activation of prolidase in hemolysates was achieved by overnight incubation at 37" C in the presence of 1 mM MnC12.
Measurement of prolidase activity in hemolysates and intact cells. Determination of prolidase with glycyl-L-proline was performed using conditions of Myara et al. (1 1) except that MnC12 was not added to reaction mixtures unless indicated. The distinction is made between "holoenzyme" meaning the active form of prolidase which is detectable without the requirement for preincubation with Mnf+ and "apoenzyme" referring to the inactive form of prolidase which requires preincubation with Mn++ for formation of a catalytically active species.
Glycyl-L-proline was purchased from Sigma (St. Louis, MO). Incubations with intact cells were performed in 10 vol of TBS pH 7.4 without shaking. Reactions were terminated by centrifugal separation of cells under conditions indicated above. A portion of the supernatant was retained for monitoring hemolysis which occurred during the reaction. The remainder of the supernatant was treated with TCA according to Myara et al. (1 1) and released proline was quantitated spectrophotometrically. When prolidase activity was assayed in hemolysates, the TCA-terminated reaction mixtures were centrifuged prior to color development in order to reduce the contribution of hemoglobin to absorbance at 5 15 nm.
Other assay procedures. Hemolysis occurring during incubation of intact cells with substrate was estimated by measurement of absorbance at 405 nm of supernatants obtained after centrifugation of reaction mixtures.
Protein was determined by the Biorad Procedure (12) . Mnf+ concentration was determined by atomic absorption spectrometry. Glycyl-L-proline was determined by amino acid analysis using a Dionex D-500 analyzer. This dipeptide elutes at a position identical to the internal standard norleucine but does not have the same retention time as any amino acid found in the serum.
RESULTS

Activation of hemolysate prolidase by manganese ions.
The requirement of prolidase for manganese ions is well established; however, in procedures currently in use for prolidase estimation (1 1) Mn++ is routinely included in incubations containing the substrate as well as in a preincubation step. It is not known if Mn++ functions as a cosubstrate in the catalytic reaction or as an inducer (or stabilizer) of the catalytically active state of the enzyme. We therefore undertook to determine I) whether erythrocytes contain prolidase in the apoenzyme form, 2) and if so, whether aprolidase present in hemolysates can be activated by exposure to Mn ions in a preincubation step or whether enzyme activity also depended on inclusion of the divalent cation in a substrate-containing reaction mixture as well as in a preincubation step.
The results presented in Table 1 indicate that most of the prolidase in hemolysates is in the catalytically inactive form. The data in Table 1 also strongly supports the hypothesis that Mn++ ions interact with an apoprolidase to produce a stable, catalytically active structure with stoichiometric and irreversibly bound metal ions but that "free" Mn is not itself directly involved in the catalytic reaction. Overnight incubation of hemolysate in 1 mM MnC12 results in a 15-30-fold enhancement of prolidase 9 Hemolysate activated by overnight incubation with 1 mM MnC12 and partially purified by DEAE cellulose according to Endo et al. (7) .
specific activity. Thus, in crude hemolysates, maximal specific activity depends on the prolonged presence of Mn++ in preincubation mixtures rather than its short-term presence in substrate containing reaction mixtures. This conclusion is supported by data obtained with activated, partially purified enzyme shown in the lower part of Table 1 . Once activated before ion exchange chromatography on DEAE cellulose (9), neither another overnight incubation with MnC12 nor the presence of Mn++ in the reaction mixture further enhanced the specific activity of the enzyme. Dialysis of the partially purified prolidase preparation resulted in only a modest decrease in enzyme activity, all of which was restored upon overnight preincubation. These results point to a high affinity of binding between Mn++ and prolidase.
These data support the following tentative conclusions that are relevant to the development of a blood transfusion based strategy for the treatment of prolidase deficiency: I ) donor erythrocytes contain primarily inactive prolidase and are therefore unlikely to be effective in reducing iminodipeptiduria; 2) if prolidase in donor erythrocytes can be "activated" before transfusion by incubation of cells with Mn++ they would constitute a greatly enhanced source of active enzyme; 3) covalent binding of Mnf+ to prolidase implies that excess unbound Mn++ could be removed from Mn-treated erythrocytes without reducing enzyme activity. The importance of this last point is that it would permit putative "activated" erythrocytes to be transfused into patients the same time infusing large amounts of Mn++ ions, which have been shown in animal studies to be neurotoxic (1 3).
Activation of erythrocyte prolidase and hydrolysis of glycyl-Lproline by intact cell. Activation of erythrocyte prolidase by extracellular Mn++ was measured after hemolysis of cells which had been incubated with and without manganese for 16 h at 37" C. The results, shown in Table 1 , indicate that Mn can enter the red cell and that hemolysates prepared from cells which had been incubated overnight in MnC12-containing buffer have approximately 15-to 30-fold more prolidase activity than erythrocytes subjected to incubations in the absence of Mn. Activation of prolidase in freshly prepared erythrocytes occurs to the same extent as in the expired blood samples.
Preincubation with Mn++ is also associated with an increase in the intracellular concentration of the metal of approximately 150-fold. The concentration of Mn++ found in hemolysates of cells preincubated in the absence of MnC12 (Table 1) was virtually identical to the levels found for control erythrocytes using neutron activation analysis (14) . The erythrocyte, once exposed to Mn++, is able to activate prolidase, to retain the enzyme in the active form after excess Mn++ is removed from the buffer by centrifugation and to internalize glycyl-L-proline when it is present at low (1 mM) concentration. The velocity of glycyl-Lproline hydrolysis in intact cells is only 1/80 that of the hemolysate (Table 1) . It is, therefore, apparent that the kinetic parameters of iminodipeptide hydrolysis by activated erythrocytes will reflect those of the rate-limiting step, membrane transport, rather than those of the enzyme. Figure 1 shows a comparison of Lineweaver-Burke plots for hydrolysis of glycyl-Lproline by intact cells that had been preincubated overnight with and without Mn. A corresponding plot for activated hemolysate prolidase is also shown.
Kinetics of glycyl-L-proline hydrolysis.
The kinetic parameters Vmax and Km obtained from these graphs are summarized in Table 2 along with comparable values obtained by other investigators. In all cases velocities for glycyl-L-proline hydrolysis by intact cells are considerably lower than velocities for hemolysates. Both King and Kuchel(l5) and Endo et al. (9) used erythrocytes that had not been exposed to Mn++.
The difference between the Vmax for unactivated erythrocytes noted by us and by King and Kuchel(15) may be due to the use of different procedures. King and Kuchel(15) used nucleomagnetic resonance to estimate both intra-and extracellular proline, whereas we and Endo et al. (9) used Chinard reagent to measure extracellular proline only. Using the same procedures as Endo, our estimate of the V, , , for activated erythrocytes is 28-fold higher than for our unactivated erythrocytes and 10-fold higher than King and Kuchel's value for V, , , in unactivated cells.
The capacity of activated erythrocyte for iminodipeptide hydrolysis. The ability of activated erythrocytes to contribute to reclamation of proline through hydrolysis of plasma iminodipeptides depends on three factors. These are the kinetic parameters of the coupled iminodipeptide transport-prolidase system, the number of activated erythrocytes and the plasma iminodipeptide concentration. 3 Unactivated cells. Table 3 shows velocity values that correspond to various hypothetical plasma glycyl-L-proline concentrations in the "physiologic" range. Velocities are calculated as mmo1/24 h to facilitate comparison with the magnitude of daily iminodipeptide excretion by patients with prolidase deficiency. Taking 25 mmol of iminodipeptide excreted per day as the average value reported for patients with this phenotype, the velocities calculated have also been transformed into "percent of daily iminodipeptide output hydrolyzed per transfusion unit of erythrocytes."
The data in Table 3 indicate that the effect of manganese activation is greater at higher substrate concentrations. If, for example the concentration of iminodipeptides in plasma were to reach 1 mM, complete recovery of proline could occur due to the activity of erythrocyte prolidase present in less than 3 U of activated donor erythrocytes. We consider the relationship between plasma concentrations of iminodipeptide and the source of those substrates.
The stability of activated erythrocyte prolidase. Prolidase activity in activated erythrocytes was normally measured within 2 h of placing the activated cells into a manganese free buffer. If enzyme replacement by infusion of activated erythrocytes is to be considered as a potential therapeutic tool it is necessary to demonstrate long-term stability of the holoenzyme form of prolidase within the cells after removal of extracellular MnC12. Hydrolysis of glycyl-L-proline in activated cells remains at least 6-fold higher than in unactivated cells during the 13 days that the cells were stored under sterile conditions at room temperature in the absence of Mn++. Specific activities of activated erythrocytes were between 1.9 and 2.4 pmol/ml/h during this interval. Longer periods of storage resulted in virtually complete hemolysis of both activated and unactivated cells.
DISCUSSION
The demonstration that prolidase occurs in an inactive form within human erythrocytes suggests a reason why attempts to cure iminodipeptiduria by infusion of normal erythrocytes were unsuccessful. In a transfused subject, iminodipeptide substrates would encounter a membrane-enclosed apoenzyme rather than the solubilized activated holoenzyme detected by the Myara procedure (1 1). The use of Mn to activate erythrocyte prolidase has been the starting point for these investigations. Although Mn+* activation of prolidase in tissue extracts has been demonstrated using a variety of enzyme sources, it has never been shown whether prolidase present within intact cells can be activated by addition of Mn" to the extracellular fluid without compromising the integrity of the cells. Previous studies showed that the metal ion is covalently bound to a sulfur atom that is required for catalytic activity (16) . Recent work indicates that preincubation with Mn stabilizes fibroblast prolidase against thermal inactivation (17) . Our results indicated that I) the membrane is permeable to Mn++; 2) MnC+ entering the cell is not completely sequestered by either membrane phospholipids or by other proteins; and 3) prolidase in situ is in a state in which its active site is accessible to Mn ions.
The prospects for successful treatment of prolidase deficiency using transfusion of affected persons with manganese activated erythrocytes depends upon the capacity of the donor erythrocytes to hydrolyze iminodipeptides in relation to the amounts of these substrates to which these cells would be exposed. The recovery of free imino acids would be slower at lower plasma iminodipeptide concentrations.
Scriver (18) found a value of 10 pM for glycyl-L-proline in patients with bone disease and Freij et al. (19) reported values of 24 pm for glycyl-L-proline in prolidase-deficient patients. Other workers reported that this iminodipeptide was completely absent from plasma of prolidase-deficient patients. Values for plasma iminodipeptide concentrations are scarce in the patients as well as normal subjects. These reports of low or absent iminodipeptide in plasma are based on fasting conditions. Under these conditions the major source of urinary iminodipeptides in prolidase deficient subjects is expected to be the turnover of collagen. Based on hydroxyproline excretion in patients, the turnover of collagen has been estimated to range from 1-6 g/day (5). Collagen turnover cannot be the only, or even the major, source of iminodipeptides in urine. The ratio of proline to hydroxyproline residues in collagen has been estimated at 1.1-1.6, however iminodipeptides containing proline are frequently found in 5-to 10-fold excess compared to hydroxyproline containing dipeptides in the urine of prolidase-deficient patients. These findings suggest that proteins other than collagen are precursors of urinary iminodipeptides.
A role for dietary protein as the source of the iminodipeptide in urine is also indicated by gelatin loading studies performed on human subjects (20). These studies suggest that plasma levels of iminodipebtide increase rapidly after ingestion of a protein meal. In vrolidase deficient subiects these substrates enter the blood via-an intestinal dipepti& trarisport system that is genetically and kinetically distinct from amino acid transporters (2 1). Such transient increases in plasma iminodipeptide concentrations have been documented in human studies, in which plasma peptide-bound hydroxyproline reaches 0.25-0.35 mM within three hours of a gelatin meal (22) and in rats, in which glycylproline reaches 0.6 mM in mesenteric plasma within 10 min of an intraluminal injection of this substrate (23).
The principal source of urinary iminodipeptides in prolidaseactivity for at least 2 wk. In a test tube such cells can convert glycyl-L-proline to free amino acids at a rate 20 times more than cells which have not been exvosed to Mn. Two important questions remain: 1 ) does the manganese activation procedure compromise the longevity or the functional integrity of the erythrocyte? and 2) does transfusion of patients with Mn-loaded erythrocytes introduce potentially toxic amounts of metal into the body? If these questions can be answered in the negative by animal studies, then we suggest that the manganese-activated erythrocyte system be considered as a serious candidate for clinical trial in cases of prolidase deficiency. deficient individuals is therefore not likely to be the steady 18. Scriver CR 1964 Glycylproline in the urine of humans with bone disease. Can 
